复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.01.019

Abstract

Abstract: Objective The aim of this study was to investigate the clinical efficacy of compound glycyrrhizin and adenosylmethionine succinate combination in treatment of patients with alcoholic hepatitis (AH) with cholestasis and its influences on serum soluble vascular adhesion molecule 1 (sVCAM 1), phospholipid transporter (PLTP) and oxidative stress parameters. Methods 114 patients with AH and hyperbilirubinemia were recruited in Department of Gastroenterology in our hospital, and were divided randomly into observation (n=57) and control group (n=57). The patients in control group was treated with intravenous adenosylmethionine succinate injection, and those in the observation group were treated with compound glycyrrhizin and adenosylmethionine combination for four weeks. Serum sVCAM 1, PLTP, malondialdehyde ( MDA), glutathione peroxidase (GST-Px) and superoxide dismutase (SOD) levels were detected. Results At the end of treatment, serum bilirubin level in the observation group was (24.6±6.4) μmol/L, which was significantly lower than in the control group, serum alanine aminotransferase level was (36.1±11.4) U/L, much lower than in the control group, serum aspartate aminotransferase level was (45.3±14.8) U/L, significantly lower than in the control, serum alkaline phosphatase level was (81.9±21.3) U/L, significantly lower than [(122.3±35.8) U/L in the control; serum sVCAM 1 level was (453.3±31.8) ng/mL, which was significantly lower than [(573.4±41.2) ng/mL, P<0.05] in the control, and serum PLTP level was (3.6±0.4) pg/mL, significantly lower than in the control; serum MDA level was (23.8±2.8) mmol/L, much lower than in the control, while serum GST-Px level was (115.5±8.2) mmol/L, which was significantly higher than and serum SOD level was (186.3±10.6) U/L, significantly higher than in the control.Conclusion The intravenous administration of compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis with intrahepatic cholestasis could improve liver function index normalization and subsiding jaundice, which might be related to the decreased serum sVCAM 1 and PLTP levels, and the inhibition of oxidative stress response, and warrants further investigation.

Key words: Alcoholic hepatitis, Cholestasis, Compound glycyrrhizin, Adenosylmethionine succinate, Soluble vascular adhesion molecule 1, Phospholipid transporter, Oxidative stress, Therapy

Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis[J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.

References

[1] 孙红菊, 王衍颜, 徐丛聪, 等. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究. 实用肝脏病杂志, 2020, 23(1): 54-57.
[2] Vakhrushev YM, Lukashevich АР, Penkina IA, et al. Comparative analysis of bile acid spectrum in non-alcoholic fatty liver disease and cholelithiasis. Ter Arkh, 2019, 91(2): 48-51.
[3] Salavrakos M, Piessevaux H, Komuta M, et al. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J Clin Gastroenterol, 2019, 53(10): 772-778.
[4] Ivashkin VT, Maevskaya MV, Kobalava ZD, et al. Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol, 2018, 64(3): 208-219.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 170-176.
[6] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志, 2016, 19(6): 771-781.
[7] Peeraphatdit TB, Simonetto DA, Shah VH. Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from nash and cholestasis. J Hepatol, 2018, 69(2): 275-277.
[8] Furuya S, Argemi J, Uehara T, et al. A novel mouse model of acute-on-chronic cholestatic alcoholic liver disease: a systems biology comparison with human alcoholic hepatitis. Alcohol Clin Exp Res, 2020, 44(1): 87-101.
[9] Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microrna profiling in alcoholic hepatitis reveals a role for microrna-182 in liver injury and inflammation. Gut, 2016, 65(9): 1535-1545.
[10] Beyolu D, Idle JR. Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy. Metabolites, 2020, 10(2): E50.
[11] Schulz M, Beha D, Plehm K, et al. High prevalence of anti-hepatitis e virus antibodies in outpatients with chronic liver disease in a university medical center in germany. Eur J Gastroenterol Hepatol, 2016, 28(12): 1431-1436.
[12] Yao M, Wang L, Leung PSC, et al. The clinical significance of gp73 in immunologically mediated chronic liver diseases: experimental data and literature review. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
[13] 池肇春. 肠道屏障功能障碍与酒精性肝病研究进展. 世界华人消化杂志, 2019, 27(19): 1179-1192.
[14] Salavrakos M, Piessevaux H, Komuta M, et al. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J Clin Gastroenterol, 2019, 53(10): 772-778.
[15] Ezhilarasan D. Oxidative stress is bane in chronic liver diseases: clinical and experimental perspective. Arab J Gastroenterol, 2018, 19(2): 56-64.
[16] Haidari F, Hojhabrimanesh A, Helli B, et al. An energy-restricted high-protein diet supplemented with β -cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: a randomized controlled trial. Nutrit Res, 2020, 73(5): 13-15.
[17] Shipovskaya AA, Dudanova OP. Intrahepatic cholestasis in nonalcoholic fatty liver disease. Ter Arkh, 2018, 90(2): 69-74.
[18] 徐贝贝, 李银玲, 王炳元. 酒精性肝病相关危险因素的研究进展. 中华肝脏病杂志, 2017, 25(5): 397-400.
[19] Karimani A, Heidarpour M, Moghaddam Jafari A. Protective effects of glycyrrhizin on sub-chronic diazinon-induced biochemical, hematological alterations and oxidative stress indices in male Wistar rats. Drug Chem Toxicol, 2019, 42(3): 300-308.
[20] Wang Y, Chen Q, Shi C, et al. Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress. Mol Med Rep, 2019, 20(5): 4081-4090.
[21] Sun Y, Shao C, Qu H, et al. Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: a case report. Medicine (Baltimore), 2018, 97(37): e12395.

Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[11]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[12]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[13]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.
[14]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.
[15]	Zhang Hua, Sun Baofeng, Liu Shiqi. Combination of oxaliplatin and capecitabine plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis [J]. Journal of Practical Hepatology, 2021, 24(1): 107-110.